Lilly’s early-stage M&A quest finds $1.5B deal for Calytrix’s blood cancer work
Eli Lilly's business development team has inked 14 buyouts this year so far, with Calytrix Bio tucking into the pharma’s oncology pipeline.
Eli Lilly's business development team has inked 14 buyouts this year so far, with Calytrix Bio tucking into the pharma’s oncology pipeline.
comments(0)
5-min edit window · permanent after that